Vitamin K2 (MK-7): The Traffic Cop That Keeps Calcium Out of Your Arteries

The Oasis Health Journal · Submitted June 27, 2026 · 4:28 PM EDT

Calcium has one job, and that job is to be hard. It is great at it. Calcium builds your bones, it builds your teeth, and given a quiet afternoon and no supervision, it will also start building a tiny limestone cave inside your arteries. That last project was not on the to-do list.

The clinical name for limestone-cave artery is coronary artery calcification, or CAC. It happens to be one of the better predictors we have of future heart trouble. Which raises a reasonable question. Calcium is supposed to report to your skeleton. Who is in charge of keeping it from wandering off into your blood vessels.

The answer is a protein with a forgettable name and a serious job: matrix Gla protein, or MGP. Picture MGP as a traffic cop posted in your artery wall, waving calcium past and saying nothing to see here, keep moving toward the bone. The catch is that the traffic cop does not clock in unless something activates him. The thing that activates him is vitamin K.

No vitamin K, no working traffic cop. Inactive MGP just leans against the wall while calcium parks wherever it likes. You can actually measure the un-activated version in blood. It goes by dp-ucMGP, which is a fine WiFi password and a terrible icebreaker. Higher levels mean your cop is asleep at the post.

The 2026 trial that finally tested it

For years this was a tidy theory with thin human proof. Then in June 2026 the VitaK-CAC trial showed up in JAMA Cardiology, and that is the part worth your attention.

Dutch researchers randomized 180 adults who already had some coronary calcium (scores of 50 to 400 Agatston units, so mild to moderate, not a crisis). Half took 360 micrograms a day of vitamin K2 as MK-7. Half took a placebo. Everyone got CT scans for two years. About 75 people per group made it to the finish line, and roughly 78 percent were on statins the entire time, so this was stacked on top of real treatment, not instead of it.

The placebo group's calcium score climbed from 145 to 214. The K2 group climbed from 135 to 184. Read that carefully: calcification still got worse in both groups. It just got worse about 30 percent slower with K2, and the difference was statistically significant. The researchers figured the yearly jump in calcium score shrank by roughly 19 units with treatment. Blood work backed up the mechanism, too. The lazy un-activated MGP rose less in the K2 group, which is a sign the vitamin was actually doing the thing it is supposed to do.

Now the part the supplement ads skip

The researchers themselves called the effect 'modest.' That is their word, not mine.

And there are real asterisks. This trial measured calcium on a scan. It did not measure heart attacks or deaths, which are the outcomes that actually matter, and nobody has shown K2 budges those yet. An editorial in the same issue called the finding 'intriguing' and then asked, very politely, for bigger and longer trials before anyone throws a parade.

There is also a genuinely strange wrinkle. Calcified plaque is hard, and hard plaque tends to be stable plaque. The soft, greasy kind is what ruptures and causes heart attacks. So one cardiologist reviewing the trial raised a fair worry: if you shrink the hard calcified stuff, can you be sure you are not leaving more of the soft dangerous stuff behind. Nobody knows yet. Calcium is the villain in one chapter and possibly a bodyguard in the next.

K2 is also not a universal de-scaler. A separate randomized trial in Circulation gave vitamin K2 plus vitamin D to people with aortic valve calcification and found essentially nothing. So the artery result is promising and specific, not a magic solvent for every calcium deposit you own.

K1, K2, and where this stuff actually lives

Quick family tree. Vitamin K1 is the kind in leafy greens, and your liver mostly grabs it for blood clotting. Vitamin K2 (the menaquinones) is the kind that seems to make it out to your bones and arteries. MK-7 is a long-lasting form of K2, which is a roundabout way of saying it sticks around in your blood long enough that one dose a day keeps levels steady.

For food, the undisputed champion is natto, a fermented soybean dish with the texture of regret and the K2 content of a small pharmacy. If natto is a bridge too far, aged cheeses and other fermented foods carry menaquinones as well. This is the rare health article where the cheese board is the wellness section.

K2 also likes to travel with vitamin D, since D helps you absorb calcium and K2 helps you aim it. That is why so many formulas pair them as vitamin D3 with K2, and why bone-and-heart blends like K-Force exist. If you want it solo, plain vitamin K2 is easy to find, and plenty of people pair it with magnesium, the other quiet mineral your bones keep texting about.

One warning that is not a joke

If you take warfarin (Coumadin) or a similar blood thinner, do not start vitamin K in any form without talking to your doctor first. Vitamin K is literally the thing those drugs are designed to work against, and even big swings in your intake can throw your numbers off. This is the one spot to be boring and careful on purpose.

For everyone else, the trial team's own summary was refreshingly low key: it probably does no harm, and it might do some good. That is not a miracle headline. It is just an honest one, which is harder to find.

If you do go looking, this is where professional-grade actually means something. We source our supplements fresh per order instead of letting bottles slowly fade on a warehouse shelf. That makes shipping a little slower and potency a little higher. For a fat-soluble vitamin you plan to take for years, the wait earns its keep.

This article is for education only and is not medical advice. Talk to a qualified healthcare professional before starting any supplement, especially if you take medication or have a medical condition.

Sources

1. Vossen LM, de Leeuw PW, Schurgers LJ, et al. Two Years of Menaquinone-7 Supplementation and Coronary Artery Calcification: A Randomized Clinical Trial. JAMA Cardiology, 2026.
2. Blaha MJ, Choi S. Coronary Artery Calcium Progression: A Useful Outcome in Clinical Trials? (Editorial). JAMA Cardiology, 2026.
3. American College of Cardiology. VitaK-CAC: Menaquinone-7 Attenuates CAC in CAD (Journal Scan), 2026.
4. TCTMD. Vitamin K Supplementation May Reduce Coronary Calcification: VitaK-CAC, 2026.
5. Vossen LM, et al. Menaquinone-7 Supplementation to Reduce Vascular Calcification in Patients with Coronary Artery Disease: Rationale and Study Protocol (VitaK-CAC). PMC.
6. Diederichsen ACP, et al. Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial. Circulation, 2022.
7. NIH Office of Dietary Supplements. Vitamin K: Fact Sheet for Health Professionals.